Payment overview · 2025
General Payments
$2,335.82
139 reported records · 24 companies
Healthcare provider profile · identity verified
Alvin Manuel Schmidt, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WEST ORANGE, NJ · NPI 1275640187
Verified facts
What the public records show
CMS Open Payments records show Alvin Manuel Schmidt, MD received $2,335.82 in general payments during 2025 across 139 reported records.
AstraZeneca Pharmaceuticals LP accounted for 12.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Farxiga, Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $283.34 | 12.1% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $259.83 | 11.1% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.30 | 9.7% | 17 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $203.33 | 8.7% | 13 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $175.06 | 7.5% | 17 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $162.76 | 7.0% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $161.92 | 6.9% | 12 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $132.02 | 5.7% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $124.99 | 5.3% | 7 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $103.93 | 4.5% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $90.23 | 3.9% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $74.18 | 3.2% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $52.80 | 2.3% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.38 | 2.2% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $34.65 | 1.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.56 | 1.5% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.40 | 1.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.06 | 1.2% | 2 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $20.83 | 0.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.97 | 0.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $17.36 | 0.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.87 | 0.7% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.38 | 0.7% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.67 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,335.82 | 139 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $208.28 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.44 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $165.97 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $162.76 | 8 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $161.92 | 12 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $132.02 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $129.64 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $125.88 | 9 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $124.99 | 7 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $105.42 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $103.93 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $97.99 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $97.91 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $90.23 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $84.73 | 9 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.92 | 6 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $74.18 | 4 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $52.80 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $50.38 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.42 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.42 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.42 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $34.40 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.56 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.91 | 2 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $19.39 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.87 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.38 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.16 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 72 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 98 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 25 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
87 | 24 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
98 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
72 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 931 | 254 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 740 | 209 |
| Alprazolam | Alprazolam | 590 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 442 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 388 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 318 | 84 |
| Metformin Hcl Er | Metformin Hcl | 283 | 74 |
| Lorazepam | Lorazepam | 261 | 61 |
| Losartan Potassium | Losartan Potassium | 253 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 252 | 80 |
| Zolpidem Tartrate | Zolpidem Tartrate | 230 | 54 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 219 | 61 |
| Simvastatin | Simvastatin | 212 | 63 |
| Trazodone Hcl | Trazodone Hcl | 194 | 57 |
| Ezetimibe | Ezetimibe | 191 | 56 |
| Potassium Chloride | Potassium Chloride | 160 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 158 | 48 |
| Irbesartan | Irbesartan | 147 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 40 |
| Metformin Hcl | Metformin Hcl | 145 | 43 |
| Allopurinol | Allopurinol | 140 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 132 | 35 |
| Gabapentin | Gabapentin | 127 | 31 |
| Furosemide | Furosemide | 126 | 35 |
| Omeprazole | Omeprazole | 122 | 38 |
| Sertraline Hcl | Sertraline Hcl | 119 | 30 |
| Meloxicam | Meloxicam | 115 | 40 |
| Glipizide Er | Glipizide | 112 | 30 |
| Telmisartan | Telmisartan | 108 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 102 | 28 |
| Ozempic | Semaglutide | 98 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 90 | 35 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 90 | 21 |
| Lisinopril | Lisinopril | 87 | 24 |
| Synthroid | Levothyroxine Sodium | 87 | 24 |
| Diazepam | Diazepam | 85 | 23 |
| Valsartan | Valsartan | 84 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 83 | 18 |
| Donepezil Hcl | Donepezil Hcl | 76 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 75 | 17 |
| Azithromycin | Azithromycin | 74 | 61 |
| Eliquis | Apixaban | 72 | 14 |
| Amoxicillin | Amoxicillin | 71 | 59 |
| Bupropion Xl | Bupropion Hcl | 67 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 17 |
| Spironolactone | Spironolactone | 63 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 61 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 20 |
| Montelukast Sodium | Montelukast Sodium | 59 | 19 |
| Finasteride | Finasteride | 58 | 16 |
| Valacyclovir | Valacyclovir Hcl | 58 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | 14 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Clonazepam | Clonazepam | 48 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | suppressed |
| Eszopiclone | Eszopiclone | 47 | suppressed |
| Atenolol | Atenolol | 46 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | 11 |
| Carvedilol | Carvedilol | 45 | suppressed |
| Famotidine | Famotidine | 43 | 11 |
| Celecoxib | Celecoxib | 42 | 12 |
| Prednisone | Prednisone | 40 | 32 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 32 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | 11 |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 20 |
| Livalo | Pitavastatin Calcium | 27 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 17 |
| Temazepam | Temazepam | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 15 |
| Ramipril | Ramipril | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 21 | 16 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Klor-Con M10 | Potassium Chloride | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Silodosin | Silodosin | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Repaglinide | Repaglinide | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 17 | suppressed |
| Verapamil Er | Verapamil Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 16 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Pregabalin | Pregabalin | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 15 | suppressed |
| Baclofen | Baclofen | 15 | 12 |
| Gemtesa | Vibegron | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Ambien | Zolpidem Tartrate | 13 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 11 | suppressed |
| Perphenazine | Perphenazine | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,335.82 · 139 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GVOKE HYPOPEN, Heplisav-B, IBSRELA, ImmunoCAP, JARDIANCE, KISUNLA, Kerendia, LEQVIO, Leqembi, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PRECIVITYAD2, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error